1. James Chih-Hsin Yang, Date: April 29-30, 2017
Meeting Venue: Auditorium 301, NTUH International Convention Center
April 29
Topic
Speaker
Moderator
01:30-02:00 PM
Registration
02:00-02:10 PM
Opening Remark
Ann-Lii Cheng
National Taiwan University Hospital, Taipei, Taiwan
Kazuhiko Nakagawa
Kindai University Faculty of Medicine, Osaka, Japan
02:10-02:50 PM
Recent progress and future perspectives of cancer immunotherapy
Yutaka Kawakami, MD, PhD
Keio University School of Medicine, Tokyo, Japan
James Chih-Hsin Yang,
02:50-03:10 PM
Ongoing Japan-Taiwan Phase I Trials: durvalumab plus ramucirumab
Chia-Chi (Josh) Lin, MD, PhD
James Chih-Hsin Yang
03:10-03:30 PM
Ongoing Japan-Taiwan Phase I Trials: atezolizumab plus erlotinib
Brigette BY Ma, MBBS, MD
Prince of Wales Hospital, Hong Kong, China
03:30-03:50 PM
Pharmaceutical Company Pipelines: Boehringer-Ingelheim
Gerd Munzert, MD
Boehringer Ingelheim Pharma GmbH & Co. KG, XXX, Germany
03:50-04:05 PM
Coffee Break
04:05-04:45 PM
Exemplification of Drug Development: Nano-liposomal irinotecan (MM398)
Li-Tzong Chen, MD, PhD
National Health Research Institute, Tainan, Taiwan
04:45-05:05 PM
Cancer Immunotherapy Combination: Head and neck cancer
Naomi Kiyota, MD, PhD
Kobe University Hospital, Kobe, Hyogo, Japan
05:05-05:25 PM
Cancer Immunotherapy Combination: Non-small cell lung cancer
Hidetoshi Hayashi, MD, PhD
05:25-05:45 PM
Pharmaceutical Company Pipelines: Daiichi Sankyo
Koichi Akahane MD
Daiichi Sankyo, Tokyo, Japan
05:45-05:55 PM
Wrap Up on Day One

2. Date: April 29-30, 2017
Meeting Venue: Auditorium 301, NTUH International Convention Center
April 30
Topic
Speaker
Moderator
07:30-08:00 AM
Registration
08:00-08:10 AM
Highlight on Day One
Chia-Chi (Josh) Lin, MD, PhD
National Taiwan University Hospital, Taipei, Taiwan
08:10-08:20 AM
Ongoing Japan-Taiwan Phase I Trials: HDM201
Noboru Yamamoto, MD, PhD
National Cancer Center Hospital, Tokyo, Japan
James Chih-Hsin Yang,
08:20-08:40AM
Complete Japan-Taiwan Phase I Trials: sonidegib (LDE225)
Yuichi Ando, MD, PhD
Nagoya University Hospital, Nagoya, Aichi, Japan
Discussant:
James Chih-Hsin Yang
08:40-09:00 AM
Jih-Hsiang Lee, MD
09:00-09:20 AM
Hironobu Minami, MD, PhD
Kobe University Hospital, Kobe, Hyogo, Japan
09:20-09:40 AM
Pharmaceutical Company Pipelines: Novartis
(TBC)
09:40-09:55 AM
Coffee Break
09:55-10:15 AM
Cancer Immunotherapy Combination: Gastric cancer
Toshihiko Doi, MD, PhD (TBC)
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
10:15-10:35 AM
Cancer Immunotherapy Combination: Colon cancer
Hisato Kawakami, MD, PhD
Kindai University Faculty of Medicine, Osaka, Japan
10:35-10:55 AM
Cancer Immunotherapy Combination: How to select the best cancer immunotherapy combination trials for our patients?
Shigehisa Kitano MD, PhD
10:55-11:15 AM
Pharmaceutical Company Pipelines: Roche
11:15-11:35 AM
Pharmaceutical Company Pipelines: Eli Lilly
11:35-11:50 AM
Concluding Remarks
Ann-Lii Cheng, MD, PhD
Kazuhiko Nakagawa, MD, PhD